What type of study is this?

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses

View Full Paper

Ask AI

Bookmark

Authors

This clinical trial reports a CRS rate of 80% in patients with RRMM receiving talquetamab, indicating variation by step-up dose.

Cytokine release syndrome (CRS) occurred at a high rate of 80% during talquetamab treatment.
Statistical comparisons revealed significant differences in CRS rates between the fourth dose and earlier step-up doses.
A multivariate analysis identified predictors of CRS, emphasizing. the impact of T-cell therapy.
These findings suggest that administering talquetamab's fourth dose in outpatient settings is feasible, potentially lowering healthcare costs.

Hamadeh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark